Dr. Wenning Qin is Senior Vice President, Innovation and Process Development, at eGenesis. She earned a B.S. in Public Health from Tongji Medical University (Wuhan, China), an M.S. in cardiovascular physiology from the same institution, and a Ph.D. in cardiovascular pharmacology from Southern Illinois University (Carbondale, IL.). Her postdoctoral training was in transcriptional regulation of gene expression from Washington University School of Medicine (St. Louis, MO). She has over 25 years of experience in genome engineering and leadership in delivering results. Her previous professional associations included Monsanto Life Sciences, Pharmacia Corporation, Pfizer Inc., Biogen Idec, and the Jackson Laboratory. In her role with eGenesis, she is responsible for porcine genome engineering and innovation strategies and executions, aspiring to bringing porcine cells, tissues, and organs to clinical practice and transforming the treatment of organ failure.

‍